We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
- Authors
Saltz, Leonard B; Rosen, Lee S; Marshall, John L; Belt, Robert J; Hurwitz, Herbert I; Eckhardt, S Gail; Bergsland, Emily K; Haller, Daniel G; Lockhart, A Craig; Rocha Lima, Caio M; Huang, Xin; DePrimo, Samuel E; Chow-Maneval, Edna; Chao, Richard C; Lenz, Heinz J
- Abstract
Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the vascular endothelial growth factor receptor and multiple other growth factor receptors. We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 30, p4793
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.12.8637